These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 18676227)

  • 21. Penetration of ofloxacin into heart valves, myocardium, mediastinal fat, and sternal bone marrow in humans.
    Mertes PM; Jehl F; Burtin P; Dopff C; Pinelli G; Villemot JP; Monteil H; Dureux JB
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2493-6. PubMed ID: 1489193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vitro activity of quinupristin/dalfopristin, levofloxacin and moxifloxacin against fusidic acid and rifampicin-resistant strains of methicillin-resistant Staphylococcus aureus (MRSA) from Malaysian hospitals.
    Norazah A; Lim VK; Rohani MY; Kamel AG
    Med J Malaysia; 2005 Oct; 60(4):411-5. PubMed ID: 16570701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of cefepime in bile and gall bladder tissue after prophylactic administration in patients with extrahepatic biliary diseases.
    Petrikkos G; Kastanakis M; Markogiannakis A; Kastanakis S; Bastounis E; Antonios P; Daikos GL; Katsilambros N
    Int J Antimicrob Agents; 2006 Apr; 27(4):331-4. PubMed ID: 16563705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus.
    Howden BP; Grayson ML
    Clin Infect Dis; 2006 Feb; 42(3):394-400. PubMed ID: 16392088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Predominance of multidrug resistant strains with reduced susceptibility to fusidic acid among methicillin-resistant Staphylococcus aureus strains (MRSA) isolated in the Gdánsk region].
    Wiśniewska K; Piechowicz L; Galiński J
    Pol Merkur Lekarski; 2000 Nov; 9(53):746-50. PubMed ID: 11204320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008).
    Castanheira M; Watters AA; Mendes RE; Farrell DJ; Jones RN
    J Antimicrob Chemother; 2010 Jul; 65(7):1353-8. PubMed ID: 20430787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections.
    Saginur R; Stdenis M; Ferris W; Aaron SD; Chan F; Lee C; Ramotar K
    Antimicrob Agents Chemother; 2006 Jan; 50(1):55-61. PubMed ID: 16377667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Penetration of ceftriaxone (1 or 2 gr intravenous) into mediastinal and cardiac tissues in man].
    Viviand X; Alaya M; Lokiec F; Ennabli K; Said R; Pecking M; Martin C
    Pathol Biol (Paris); 1995 Apr; 43(4):364-9. PubMed ID: 7567130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamics of cefepime.
    Kovarik J; Rozenberg-Arska M; Visser M; Verhoef J
    Scand J Infect Dis Suppl; 1990; 74():270-3. PubMed ID: 2097715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An antibacterial hydroxy fusidic acid analogue from Acremonium crotocinigenum.
    Evans L; Hedger JN; Brayford D; Stavri M; Smith E; O'Donnell G; Gray AI; Griffith GW; Gibbons S
    Phytochemistry; 2006 Oct; 67(19):2110-4. PubMed ID: 16930645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of fusidic acid-resistant Staphylococcus aureus isolates in the community of Casablanca (Morocco).
    Elazhari M; Abu-Quatouseh LF; Elhabchi D; Zerouali K; Dersi N; Saile R; Timinouni M; Becker K
    Int J Med Microbiol; 2012 Mar; 302(2):96-100. PubMed ID: 22197537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States.
    Jones RN; Mendes RE; Sader HS; Castanheira M
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S477-86. PubMed ID: 21546624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics.
    Turnidge J
    Int J Antimicrob Agents; 1999 Aug; 12 Suppl 2():S23-34. PubMed ID: 10528784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of silver-coated dressing (Acticoat), chlorhexidine acetate 0.5% (Bactigrass), and fusidic acid 2% (Fucidin) for topical antibacterial effect in methicillin-resistant Staphylococci-contaminated, full-skin thickness rat burn wounds.
    Ulkür E; Oncul O; Karagoz H; Yeniz E; Celiköz B
    Burns; 2005 Nov; 31(7):874-7. PubMed ID: 16011879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization.
    Kachroo S; Dao T; Zabaneh F; Reiter M; Larocco MT; Gentry LO; Garey KW
    Ann Pharmacother; 2006 Mar; 40(3):381-5. PubMed ID: 16478809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survey, characterization and susceptibility to fusidic acid of Staphylococcus aureus in the Carmarthen area.
    El-Zimaity D; Kearns AM; Dawson SJ; Price S; Harrison GA
    J Antimicrob Chemother; 2004 Aug; 54(2):441-6. PubMed ID: 15269197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparison with linezolid and clindamycin.
    Lemaire S; Van Bambeke F; Pierard D; Appelbaum PC; Tulkens PM
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S493-503. PubMed ID: 21546626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective, open-label investigation of the pharmacokinetics of daptomycin during cardiopulmonary bypass surgery.
    Nguyen MH; Eells SJ; Tan J; Sheth CT; Omari B; Flores M; Wang J; Miller LG
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2499-505. PubMed ID: 21444695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Penetration of teicoplanin into heart valves and subcutaneous and muscle tissues of patients undergoing open-heart surgery.
    Frank UK; Schmidt-Eisenlohr E; Mlangeni D; Schindler M; Hoh A; Beyersdorf F; Daschner FD
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2559-61. PubMed ID: 9371368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Penetration of ciprofloxacin into heart valves, myocardium, mediastinal fat, and sternal bone marrow in humans.
    Mertes PM; Voiriot P; Dopff C; Scholl H; Clavey M; Villemot JP; Canton P; Dureux JB
    Antimicrob Agents Chemother; 1990 Mar; 34(3):398-401. PubMed ID: 2185690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.